



Universiteit
Leiden
The Netherlands

Unravelling the sugar-coating of prostate-specific antigen : method development and its application to prostate cancer research

Kammeijer, G.S.M.

Citation

Kammeijer, G. S. M. (2019, March 7). *Unravelling the sugar-coating of prostate-specific antigen : method development and its application to prostate cancer research*. Retrieved from <https://hdl.handle.net/1887/69482>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/69482>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/69482> holds various files of this Leiden University dissertation.

Author: Kammeijer, G.S.M.

Title: Unravelling the sugar-coating of prostate-specific antigen : method development and its application to prostate cancer research

Issue Date: 2019-03-07

B

BIBLIOGRAPHY

- (1) Bray, F., et al. *Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*, *CA Cancer J. Clin.*, **2018**, 68, 394-424.
- (2) Wolf, A.M., et al. *American Cancer Society guideline for the early detection of prostate cancer: update 2010*, *CA Cancer J. Clin.*, **2010**, 60, 70-98.
- (3) Yoneyama, T., et al. *Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer*, *Biochem. Biophys. Res. Commun.*, **2014**, 448, 390-396.
- (4) Kyselova, Z., et al. *Alterations in the serum glycome due to metastatic prostate cancer*, *J. Proteome Res.*, **2007**, 6, 1822-1832.
- (5) Vermassen, T., et al. *Capillary electrophoresis of urinary prostate glycoproteins assists in the diagnosis of prostate cancer*, *Electrophoresis*, **2014**, 35, 1017-1024.
- (6) Kammeijer, G.S.M., et al. *Sialic acid linkage differentiation of glycopeptides using capillary electrophoresis - electrospray ionization - mass spectrometry*, *Sci. Rep.*, **2017**, 7, 3733.
- (7) Kammeijer, G.S.M., et al. *An In-Depth Glycosylation Assay for Urinary Prostate-Specific Antigen*, *Anal. Chem.*, **2018**, 90, 4414-4421.
- (8) Schultz, M.J., et al. *Regulation of the metastatic cell phenotype by sialylated glycans*, *Cancer Metastasis Rev.*, **2012**, 31, 501-518.
- (9) Zhuo, Y.; Bellis, S.L. *Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function*, *J. Biol. Chem.*, **2011**, 286, 5935-5941.
- (10) Incidences of prostate cancer in the Netherlands from 1990-2017 from the Netherlands Comprehensive Cancer Organization: Retrieved from www.cijfersoverkanker.nl.
- (11) Blanker, M.H., et al. *Prostate cancer detection in older men with and without lower urinary tract symptoms: A population-based study*, *J. Am. Geriatr. Soc.*, **2003**, 51, 1041-1042.
- (12) Collin, S.M., et al. *Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study*, *BJU Int.*, **2008**, 102, 1400-1406.
- (13) Kheirandish, P.; Chinegwundoh, F. *Ethnic differences in prostate cancer*, *Br. J. Cancer*, **2011**, 105, 481-485.
- (14) Bruner, D.W., et al. *Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis*, *Int. J. Cancer*, **2003**, 107, 797-803.
- (15) Chen, Y.C., et al. *Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era*, *Prostate*, **2008**, 68, 1582-1591.
- (16) Valeri, A., et al. *Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives*, *Int. J. Cancer*, **2000**, 86, 883-887.
- (17) Wong, M.C., et al. *Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries*, *Eur. Urol.*, **2016**, 70, 862-874.
- (18) US Preventive Services Task Force, et al. *Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement*, *JAMA*, **2018**, 319, 1901-1913.
- (19) Nederlandse Vereniging voor Urologie, Prostaatcarcinoom, Landelijke Richtlijn; **2014**.
- (20) Ahmed, H.U., et al. *Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study*, *Lancet*, **2017**, 389, 815-822.
- (21) Gittes, R.F. *Carcinoma of the Prostate*, *N. Engl. J. Med.*, **1991**, 324, 236-245.
- (22) Gleason, D.F.; Mellinger, G.T. *Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical*



- Staging, *J. Urol.*, **1974**, 111, 58-64.
- (23) Epstein, J.I., et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, *Am. J. Surg. Pathol.*, **2005**, 29, 1228-1242.
- (24) Chan, T.Y., et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy, *Urology*, **2000**, 56, 823-827.
- (25) American Joint Committee on Cancer, *AJCC Cancer Staging Manual: Seventh edition*, Edge, S.B.; Byrd, D.R.; Compton, C.C.; Fritz, A.G.; Greene, F.L.; Trotti, A., Eds.; Springer, **2010**, pp 457-464.
- (26) Keetch, D.W., et al. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values, *J. Urol.*, **1994**, 151, 1571-1574.
- (27) Abdelkhalek, M., et al. Hemosepermia after transrectal ultrasound-guided prostatic biopsy: A prospective study, *Urol. Ann.*, **2013**, 5, 30-33.
- (28) Loeb, S., et al. Systematic review of complications of prostate biopsy, *Eur. Urol.*, **2013**, 64, 876-892.
- (29) El-Shater Bosaily, A., et al. PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer, *Contemp. Clin. Trials*, **2015**, 42, 26-40.
- (30) Day, J.R., et al. PCA3: from basic molecular science to the clinical lab, *Cancer Lett.*, **2011**, 301, 1-6.
- (31) Catalona, W.J. Management of cancer of the prostate, *N. Engl. J. Med.*, **1994**, 331, 996-1004.
- (32) Bubendorf, L., et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients, *Hum. Pathol.*, **2000**, 31, 578-583.
- (33) Janković, M.M.; Kosanović, M.M. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns, *Clin. Biochem.*, **2005**, 38, 58-65.
- (34) Peracaula, R., et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins, *Glycobiology*, **2003**, 13, 457-470.
- (35) Saldova, R., et al. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia, *Glycobiology*, **2011**, 21, 195-205.
- (36) Lilja, H., et al. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen, *J. Clin. Invest.*, **1987**, 80, 281-285.
- (37) Peter, A., et al. Semenogelin I and semenogelin II, the major gel-forming proteins in human semen, are substrates for transglutaminase, *Eur. J. Biochem.*, **1998**, 252, 216-221.
- (38) Bokhorst, L.P., et al. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*, *BJU Int.*, **2012**, 110, 1654-1660.
- (39) Foley, R.W., et al. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study, *BJU Int.*, **2016**, 118, 706-713.
- (40) Lövgren, J., et al. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids, *J. Androl.*, **1999**, 20, 348-355.
- (41) Howarth, D.J., et al. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues, *Br. J. Cancer*, **1997**, 75, 1646-1651.
- (42) Yu, H.; Diamandis, E.P. Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique, *J. Urol.*, **1995**, 153, 1004-1008.
- (43) Yu, H.; Diamandis, E.P. Prostate-specific antigen immunoreactivity in amniotic fluid, *Clin. Chem.*, **1995**, 41, 204-210.
- (44) Schmidt, S., et al. Prostate-specific antigen

- in female urine: a prospective study involving 217 women, *Urology*, **2001**, 57, 717-720.
- (45) Balk, S.P., et al. Biology of prostate-specific antigen, *J. Clin. Oncol.*, **2003**, 21, 383-391.
- (46) Gilgunn, S., et al. Aberrant PSA glycosylation—a sweet predictor of prostate cancer, *Nat. Rev. Urol.*, **2013**, 10, 99.
- (47) Mikolajczyk, S.D., et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum, *Urology*, **1997**, 50, 710-714.
- (48) Takayama, T.K., et al. Characterization of hK4 (protease), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase, *Biochemistry*, **2001**, 40, 15341-15348.
- (49) Kumar, A., et al. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2, *Cancer Res.*, **1997**, 57, 3111-3114.
- (50) Lövgren, J., et al. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2, *Biochem. Biophys. Res. Commun.*, **1997**, 238, 549-555.
- (51) Mikolajczyk, S.D., et al. Seminal plasma contains “BPSA,” a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia, *Prostate*, **2000**, 45, 271-276.
- (52) Mikolajczyk, S.D., et al. “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia, *Urology*, **2000**, 55, 41-45.
- (53) Wang, T.J., et al. Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies, *Eur. J. Biochem.*, **2000**, 267, 4040-4045.
- (54) Wang, T.J., et al. PSA concentrations in seminal plasma, *Clin. Chem.*, **1998**, 44, 895-896.
- (55) Christensson, A.; Lilja, H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen, *Eur. J. Biochem.*, **1994**, 220, 45-53.
- (56) Zhang, W.M., et al. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid, *Clin. Chem.*, **1995**, 41, 1567-1573.
- (57) Jung, K., et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?, *Clin. Chem.*, **2000**, 46, 55-62.
- (58) Lilja, H., et al. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring, *Nat. Rev. Cancer*, **2008**, 8, 268-278.
- (59) Brawer, M.K., et al. Serum Prostate-Specific Antigen and Prostate Pathology in Men Having Simple Prostatectomy, *Am. J. Clin. Pathol.*, **1989**, 92, 760-764.
- (60) Djavan, B., et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial, *Urology*, **2002**, 60, 4-9.
- (61) Catalona, W.J., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial, *JAMA*, **1998**, 279, 1542-1547.
- (62) Catalona, W.J., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening, *JAMA*, **1995**, 274, 1214-1220.
- (63) Nurmikko, P., et al. Discrimination of



- prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146, *Clin. Chem.*, **2001**, 47, 1415-1423.
- (64) Leinonen, J., et al. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin, *Clin. Chem.*, **1993**, 39, 2098-2103.
- (65) Lilja, H., et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin, *Clin. Chem.*, **1991**, 37, 1618-1625.
- (66) Stenman, U.H., et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer, *Cancer Res.*, **1991**, 51, 222-226.
- (67) Okihara, K., et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer, *J. Urol.*, **2002**, 167, 2017-2023.
- (68) Partin, A.W., et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: Results of a prospective multicenter clinical trial, *J. Urol.*, **2003**, 170, 1787-1791.
- (69) Jung, K., et al. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: Biochemical and diagnostic implications, *Clin. Chem.*, **2000**, 46, 47-54.
- (70) Jansen, F.H., et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection, *Eur. Urol.*, **2010**, 57, 921-927.
- (71) Loeb, S., et al. The prostate health index selectively identifies clinically significant prostate cancer, *J. Urol.*, **2015**, 193, 1163-1169.
- (72) Vickers, A.J., et al. A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam, *Clin. Cancer Res.*, **2010**, 16, 3232-3239.
- (73) Deras, I.L., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome, *J. Urol.*, **2008**, 179, 1587-1592.
- (74) Hessels, D., et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer, *Eur. Urol.*, **2003**, 44, 8-15; discussion 15-16.
- (75) Schalken, J.A., et al. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene, *Urology*, **2003**, 62, 34-43.
- (76) Marks, L.S.; Bostwick, D.G. Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice, *Rev. Urol.*, **2008**, 10, 175-181.
- (77) Merola, R., et al. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience, *J. Exp. Clin. Cancer Res.*, **2015**, 34, 15.
- (78) Ferro, M., et al. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml, *PLOS One*, **2013**, 8, e67687.
- (79) Nordström, T., et al. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer, *Eur. Urol.*, **2015**, 68, 139-146.
- (80) Stephan, C., et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]prostate-specific antigen-based prostate health index for detection of prostate cancer, *Clin. Chem.*, **2013**, 59, 280-288.
- (81) Laine, R.A. Invited Commentary: A calculation of all possible oligosaccharide isomers both branched and linear yields 1.05×10^{12} structures for a reducing hexasaccharide: the Isomer Barrier to development of single-method saccharide sequencing or synthesis systems, *Glycobiology*, **1994**, 4, 759-767.
- (82) Varki, A.; al., e. Essentials of Glycobiology,

- rd; Varki, A.; Cummings, R.D.; Esko, J.D.; Stanley, P.; Hart, G.W.; Aebi, M.; Darvill, A.G.; Kinoshita, T.; Packer, N.H.; Prestegard, J.H.; Schnaar, R.L.; Seeberger, P.H., Eds.: Cold Spring Harbor (NY), **2015**.
- (83) Varki, A., et al. *Symbol Nomenclature for Graphical Representations of Glycans, Glycobiology*, **2015**, 25, 1323-1324.
- (84) Ohtsubo, K.; Marth, J.D. *Glycosylation in cellular mechanisms of health and disease, Cell*, **2006**, 126, 855-867.
- (85) Karsten, C.M., et al. *Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIIb and dectin-1, Nat. Med.*, **2012**, 18, 1401-1406.
- (86) Shields, R.L., et al. *Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity, J. Biol. Chem.*, **2002**, 277, 26733-26740.
- (87) Almeida, A.; Kolarich, D. *The promise of protein glycosylation for personalised medicine, Biochim. Biophys. Acta. Gen. Subj.*, **2016**, 1860, 1583-1595.
- (88) Thomann, M., et al. *In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity, PLOS One*, **2015**, 10, e0134949.
- (89) Holst, S., et al. *Glycosylation characteristics of colorectal cancer, Adv. Cancer Res.*, **2015**, 126, 203-256.
- (90) Taniguchi, N.; Kizuka, Y. *Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics, Adv. Cancer Res.*, **2015**, 126, 11-51.
- (91) Adamczyk, B., et al. *Glycans as cancer biomarkers, Biochim. Biophys. Acta*, **2012**, 1820, 1347-1353.
- (92) Ruhaak, L.R., et al. *Developments in the identification of glycan biomarkers for the detection of cancer, Mol. Cell. Proteomics*, **2013**, 12, 846-855.
- (93) Ueda, K. *Glycoproteomic strategies: From discovery to clinical application of cancer carbohydrate biomarkers, Proteomics Clin. Appl.*, **2013**, 7, 607-617.
- (94) Kirwan, A., et al. *Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics, Biomed. Res. Int.*, **2015**, 2015, 490531.
- (95) Arrieta, O., et al. *The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis, BMC Cancer*, **2007**, 7, 28.
- (96) Duffy, M.J. *Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful?, Clin. Chem.*, **2001**, 47, 624-630.
- (97) Drake, P.M., et al. *Sweetening the Pot: Adding Glycosylation to the Biomarker Discovery Equation, Clin. Chem.*, **2010**, 56, 223-236.
- (98) Pihikova, D., et al. *Aberrant sialylation of a prostate-specific antigen: Electrochemical label-free glycoprofiling in prostate cancer serum samples, Anal. Chim. Acta*, **2016**, 934, 72-79.
- (99) Llop, E., et al. *Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes, Theranostics*, **2016**, 6, 1190-1204.
- (100) Ferrer-Batalle, M., et al. *Comparative Study of Blood-Based Biomarkers, alpha2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection, Int. J. Mol. Sci.*, **2017**, 18.
- (101) Li, Q.K., et al. *Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers, Theranostics*, **2015**, 5, 267-276.
- (102) Dwek, M.V., et al. *A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia, Clin. Chim. Acta*, **2010**, 411, 1935-1939.
- (103) Fukushima, K., et al. *alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer, Glycobiology*, **2010**, 20, 452-460.
- (104) Vermassen, T., et al. *Urinary prostate*



- protein glycosylation profiling as a diagnostic biomarker for prostate cancer, *Prostate*, **2015**, 75, 314-322.
- (105) Vermassen, T., et al. Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis, *Biochem. Med. (Zagreb)*, **2015**, 25, 439-449.
- (106) Aizpurua-Olaizola, O., et al. Mass spectrometry for glycan biomarker discovery, *TrAC, Trends Anal. Chem.*, **2018**, 100, 7-14.
- (107) Ruhaak, L.R., et al. Mass Spectrometry Approaches to Glycomic and Glycoproteomic Analyses, *Chem. Rev.*, **2018**, DOI: 10.1021/acs.chemrev.7b00732.
- (108) Tiselius, A. A new apparatus for electrophoretic analysis of colloidal mixtures, *Trans. Faraday Soc.*, **1937**, 33, 524-531.
- (109) Hjertén, S. Free zone electrophoresis, *Chromatogr. Rev.*, **1967**, 9, 122-219.
- (110) Mikkers, F.E.P., et al. High-performance zone electrophoresis, *J. Chromatogr. A*, **1979**, 169, 11-20.
- (111) Jorgenson, J.W.; Lukacs, K.D. Zone Electrophoresis in Open-Tubular Glass-Capillaries, *Anal. Chem.*, **1981**, 53, 1298-1302.
- (112) Busnel, J.M., et al. High capacity capillary electrophoresis-electrospray ionization mass spectrometry: coupling a porous sheathless interface with transient-isotachophoresis, *Anal. Chem.*, **2010**, 82, 9476-9483.
- (113) Boček, P., et al. Analytical Isotachophoresis Concept of Separation Capacity, *J. Chromatogr.*, **1978**, 160, 1-9.
- (114) Lauer, H.H.; Rozing, G.P. *High Performance Capillary Electrophoresis, a primer*; Agilent Technologies: Germany, **2009**.
- (115) Mala, Z., et al. Analytical capillary isotachophoresis after 50 years of development: Recent progress 2014-2016, *Electrophoresis*, **2017**, 38, 9-19.
- (116) Liu, J.P., et al. Capillary electrophoresis of amino sugars with laser-induced fluorescence detection, *Anal. Chem.*, **1991**, 63, 413-417.
- (117) Olivares, J.A., et al. Online Mass-Spectrometric Detection for Capillary Zone Electrophoresis, *Anal. Chem.*, **1987**, 59, 1230-1232.
- (118) Smith, R.D.; Udseth, H.R. Capillary zone electrophoresis-MS, *Nature*, **1988**, 331, 639-640.
- (119) Wojcik, R., et al. Capillary electrophoresis with Orbitrap-Velos mass spectrometry detection, *Talanta*, **2012**, 88, 324-329.
- (120) Moini, M. Simplifying CE-MS operation. 2. Interfacing low-flow separation techniques to mass spectrometry using a porous tip, *Anal. Chem.*, **2007**, 79, 4241-4246.
- (121) Himmelsbach, M. 10 years of MS instrumental developments--impact on LC-MS/MS in clinical chemistry, *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.*, **2012**, 883-884, 3-17.
- (122) Hoffmann, de E.; Stroobant, V. *Mass spectrometry: Principles and applications*, 3rd Ed., John Wiley & Sons Ltd., **2007**.
- (123) Jensen, P.H., et al. Structural analysis of N- and O-glycans released from glycoproteins, *Nat. Protoc.*, **2012**, 7, 1299-1310.
- (124) Zauner, G., et al. Protein O-glycosylation analysis, *Biol. Chem.*, **2012**, 393, 687-708.
- (125) Johnson, R.S., et al. Novel fragmentation process of peptides by collision-induced decomposition in a tandem mass spectrometer: differentiation of leucine and isoleucine, *Anal. Chem.*, **1987**, 59, 2621-2625.
- (126) Roepstorff, P.; Fohlman, J. Letter to the editors, *Biol. Mass Spectrom.*, **1984**, 11, 601-601.
- (127) Wührer, M., et al. Glycoproteomics based on tandem mass spectrometry of glycopeptides, *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.*, **2007**, 849, 115-128.
- (128) Domon, B.; Costello, C.E. A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates, *Glycoconj. J.*, **1988**, 5, 397-409.

- (129) Halim, A., et al. Assignment of saccharide identities through analysis of oxonium ion fragmentation profiles in LC-MS/MS of glycopeptides, *J. Proteome Res.*, **2014**, 13, 6024-6032.
- (130) Harvey, D.J., et al. Structural and quantitative analysis of N-linked glycans by matrix-assisted laser desorption ionization and negative ion nanospray mass spectrometry, *Anal. Biochem.*, **2008**, 376, 44-60.
- (131) Huddleston, M.J., et al. Collisional fragmentation of glycopeptides by electrospray ionization LC/MS and LC/MS/MS: methods for selective detection of glycopeptides in protein digests, *Anal. Chem.*, **1993**, 65, 877-884.
- (132) Hinneburg, H., et al. *The Art of Destruction: Optimizing Collision Energies in Quadrupole-Time of Flight (Q-TOF) Instruments for Glycopeptide-Based Glycoproteomics*, *J. Am. Soc. Mass Spectrom.*, **2016**, 27, 507-519.
- (133) Jenkins, N.; Curling, E.M. Glycosylation of recombinant proteins: problems and prospects, *Enzyme Microb. Technol.*, **1994**, 16, 354-364.
- (134) Sinclair, A.M.; Elliott, S. *Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins*, *J. Pharm. Sci.*, **2005**, 94, 1626-1635.
- (135) Taylor, M.E.; Drickamer, K. *Introduction to Glycobiology*; Oxford University Press: Oxford, **2011**.
- (136) Parekh, R.B., et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG, *Nature*, **1985**, 316, 452-457.
- (137) Pinho, S.S.; Reis, C.A. Glycosylation in cancer: mechanisms and clinical implications, *Nat. Rev. Cancer*, **2015**, 15, 540-555.
- (138) Ruhaak, L.R., et al. Plasma protein N-glycan profiles are associated with calendar age, familial longevity and health, *J. Proteome Res.*, **2011**, 10, 1667-1674.
- (139) Albrecht, S., et al. Glycosylation as a marker for inflammatory arthritis, *Cancer Biomark.*, **2014**, 14, 17-28.
- (140) Bondt, A., et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation, *J. Proteome Res.*, **2013**, 12, 4522-4531.
- (141) Lauc, G., et al. Mechanisms of disease: The human N-glycome, *Biochim. Biophys. Acta*, **2016**, 1860, 1574-1582.
- (142) Byrne, B., et al. Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells, *Drug. Discov. Today*, **2007**, 12, 319-326.
- (143) Jørgensen, T., et al. Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer, *Cancer Res.*, **1995**, 55, 1817-1819.
- (144) Wang, F.L., et al. High expression of alpha 2, 3-linked sialic acid residues is associated with the metastatic potential of human gastric cancer, *Cancer Detect. Prev.*, **2009**, 32, 437-443.
- (145) Hsu, D.K., et al. Galectins in apoptosis, *Methods Enzymol.* **2006**, 417, 256-273.
- (146) Reis, C.A., et al. Alterations in glycosylation as biomarkers for cancer detection, *J. Clin. Pathol.*, **2010**, 63, 322-329.
- (147) Jenkins, N., et al. Getting the glycosylation right: implications for the biotechnology industry, *Nat. Biotechnol.*, **1996**, 14, 975-981.
- (148) Wacker, C., et al. Glycosylation profiles of therapeutic antibody pharmaceuticals, *Eur. J. Pharm. Biopharm.*, **2011**, 79, 503-507.
- (149) Egrie, J.C.; Browne, J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP), *Br. J. Cancer*, **2001**, 84 Suppl 1, 3-10.
- (150) Fernandes, A.I.; Gregoriadis, G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics, *Int. J. Pharm.*, **2001**, 217, 215-224.
- (151) Solá, R.J.; Griebenow, K. Glycosylation of



- therapeutic proteins: an effective strategy to optimize efficacy, *BioDrugs*, **2010**, 24, 9-21.
- (152) Weikert, S., et al. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins, *Nat. Biotechnol.*, **1999**, 17, 1116-1121.
- (153) Desaire, H. Glycopeptide analysis, recent developments and applications, *Mol. Cell. Proteomics*, **2013**, 12, 893-901.
- (154) Guttman, M.; Lee, K.K. Site-Specific Mapping of Sialic Acid Linkage Isomers by Ion Mobility Spectrometry, *Anal. Chem.*, **2016**, 88, 5212-5217.
- (155) Haan, de N., et al. Linkage-specific sialic acid derivatization for MALDI-TOF-MS profiling of IgG glycopeptides, *Anal. Chem.*, **2015**, 87, 8284-8291.
- (156) Lee, E.U., et al. Alteration of terminal glycosylation sequences on N-linked oligosaccharides of Chinese hamster ovary cells by expression of beta-galactoside alpha 2,6-sialyltransferase, *J. Biol. Chem.*, **1989**, 264, 13848-13855.
- (157) Anthony, R.M., et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc, *Science*, **2008**, 320, 373-376.
- (158) Fuguet, E., et al. A fast method for pKa determination by capillary electrophoresis, *Chem. Biodivers.*, **2009**, 6, 1822-1827.
- (159) Ruhaak, L.R., et al. Hydrophilic interaction chromatography-based high-throughput sample preparation method for N-glycan analysis from total human plasma glycoproteins, *Anal. Chem.*, **2008**, 80, 6119-6126.
- (160) Reiding, K.R., et al. High-throughput profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-specific sialic acid esterification, *Anal. Chem.*, **2014**, 86, 5784-5793.
- (161) Selman, M.H., et al. Cotton HILIC SPE microtips for microscale purification and enrichment of glycans and glycopeptides, *Anal. Chem.*, **2011**, 83, 2492-2499.
- (162) Jansen, B.C., et al. LaCyTools: A Targeted Liquid Chromatography-Mass Spectrometry Data Processing Package for Relative Quantitation of Glycopeptides, *J. Proteome Res.*, **2016**, 15, 2198-2210.
- (163) Palmblad, M., et al. Improving mass measurement accuracy in mass spectrometry based proteomics by combining open source tools for chromatographic alignment and internal calibration, *J. Proteomics*, **2009**, 72, 722-724.
- (164) Mancera-Arteu, M., et al. Identification and characterization of isomeric N-glycans of human alpha-acid-glycoprotein by stable isotope labelling and ZIC-HILIC-MS in combination with exoglycosidase digestion, *Anal. Chim. Acta*, **2016**, 940, 92-103.
- (165) Stavenhagen, K., et al. Clinical Glycomics Employing Graphitized Carbon Liquid Chromatography-Mass Spectrometry, *Chromatographia*, **2015**, 78, 307-320.
- (166) Costello, C.E., et al. A glycomics platform for the analysis of permethylated oligosaccharide alditols, *J. Am. Soc. Mass. Spectrom.*, **2007**, 18, 1799-1812.
- (167) Everest-Dass, A.V., et al. Structural feature ions for distinguishing N- and O-linked glycan isomers by LC-ESI-IT MS/MS, *J. Am. Soc. Mass. Spectrom.*, **2013**, 24, 895-906.
- (168) Harvey, D.J., et al. Fragmentation of negative ions from N-linked carbohydrates, part 4. Fragmentation of complex glycans lacking substitution on the 6-antenna, *J. Mass. Spectrom.*, **2010**, 45, 528-535.
- (169) Human Metabolomics Database, Metabocard for 3'-Sialyllactose (HMDB00825), 2005 ed.: **2005**; <http://www.hmdb.ca/metabolites/HMDB00825>
- (170) Human Metabolomics Database, Metabocard for 6'-Sialyllactose (HMDB06569): **2005**; <http://www.hmdb.ca/metabolites/HMDB06569>
- (171) Hardy, M., et al. *Techniques in Glycobiology*; Dekker, Inc: New York, **1997**.
- (172) Geiser, L., et al. Determination of pKa values by capillary zone electrophoresis with a dynamic coating procedure, *J. Sep. Sci.*, **2005**, 28, 2374-2380.

- (173) Galuska, S.P., et al. Glycomic strategy for efficient linkage analysis of di-, oligo- and polysialic acids, *J. Proteomics*, **2012**, 75, 5266-5278.
- (174) Gahoual, R., et al. Full antibody primary structure and microvariant characterization in a single injection using transient isotachopheresis and sheathless capillary electrophoresis-tandem mass spectrometry, *Anal. Chem.*, **2014**, 86, 9074-9081.
- (175) Haselberg, R., et al. Low-flow sheathless capillary electrophoresis-mass spectrometry for sensitive glycoform profiling of intact pharmaceutical proteins, *Anal. Chem.*, **2013**, 85, 2289-2296.
- (176) Ramautar, R., et al. Enhancing the coverage of the urinary metabolome by sheathless capillary electrophoresis-mass spectrometry, *Anal. Chem.*, **2012**, 84, 885-892.
- (177) Heemskerk, A.A.M., et al. Coupling porous sheathless interface MS with transient-ITP in neutral capillaries for improved sensitivity in glycopeptide analysis, *Electrophoresis*, **2013**, 34, 383-387.
- (178) Leymarie, N., et al. Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012, *Mol. Cell. Proteomics*, **2013**, 12, 2935-2951.
- (179) Catalona, W.J., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer, *N. Engl. J. Med.*, **1991**, 324, 1156-1161.
- (180) Carlsson, S., et al. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study, *BMJ*, **2014**, 348, g2296.
- (181) Moyer, V.A.; U.S. Preventive Services Task Force,. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement, *Ann. Intern. Med.*, **2012**, 157, 120-134.
- (182) Hsiao, C.J., et al. Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia, *Dis. Markers*, **2016**, 2016, 8915809.
- (183) Sarrats, A., et al. Glycan characterization of PSA 2-DE subforms from serum and seminal plasma, *OMICS*, **2010**, 14, 465-474.
- (184) Tajiri, M., et al. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach, *Glycobiology*, **2008**, 18, 2-8.
- (185) Gale, D.C.; Smith, R.D. Small volume and low flow-rate electrospray ionization mass spectrometry of aqueous samples, *Rapid Commun. Mass Spectrom.*, **1993**, 7, 1017-1021.
- (186) Wilm, M.; Mann, M. Analytical properties of the nanoelectrospray ion source, *Anal. Chem.*, **1996**, 68, 1-8.
- (187) Bonvin, G., et al. Capillary electrophoresis-electrospray ionization-mass spectrometry interfaces: fundamental concepts and technical developments, *J. Chromatogr. A*, **2012**, 1267, 17-31.
- (188) Covey, T.R., et al. Atmospheric pressure ion sources, *Mass Spectrom. Rev.*, **2009**, 28, 870-897.
- (189) Juraschek, R., et al. Nanoelectrospray-more than just a minimized-flow electrospray ionization source, *J. Am. Soc. Mass Spectrom.*, **1999**, 10, 300-308.
- (190) Schmidt, A., et al. Effect of different solution flow rates on analyte ion signals in nano-ESI MS, or: when does ESI turn into nano-ESI?, *J. Am. Soc. Mass Spectrom.*, **2003**, 14, 492-500.
- (191) Nguyen, S.; Fenn, J.B. Gas-phase ions of solute species from charged droplets of solutions, *Proc. Natl. Acad. Sci. U.S.A.*, **2007**, 104, 1111-1117.
- (192) Zhu, Y.; Nugent, K.D., *Method and Apparatus for Nano-Capillary/Micro Electrospray for use in Liquid Chromatography-Mass Spectrometry*, United States, US8227750 B1, **2012**.
- (193) *CaptiveSpray nanoBooster - The Revolution*



- in Proteomics Ionization: Bruker Daltonics Inc.*, **2013**.
- (194) Meyer, J.G.; Komives, E.A. *Charge State Coalescence During Electrospray Ionization Improves Peptide Identification by Tandem Mass Spectrometry*, *J. Am. Soc. Mass Spectrom.*, **2012**, 23, 1390-1399.
- (195) Marx, K., et al. *Identification of a Second N-glycosylation Site in a Human PSA Sample by Combined CID/ETD Fragmentation*, *Bruker Daltonics Inc.*, **2012**, Application Note LCMS-76.
- (196) Peterman, S.M.; Mulholland, J.J. *A novel approach for identification and characterization of glycoproteins using a hybrid linear ion trap/FT-ICR mass spectrometer*, *J. Am. Soc. Mass Spectrom.*, **2006**, 17, 168-179.
- (197) Mysling, S., et al. *Utilizing ion-pairing hydrophilic interaction chromatography solid phase extraction for efficient glycopeptide enrichment in glycoproteomics*, *Anal. Chem.*, **2010**, 82, 5598-5609.
- (198) Heemskerk, A.A.M., et al. *Ultra-low flow electrospray ionization-mass spectrometry for improved ionization efficiency in phosphoproteomics*, *Anal. Chem.*, **2012**, 84, 4552-4559.
- (199) Sarg, B., et al. *Comparing and Combining Capillary Electrophoresis Electrospray Ionization Mass Spectrometry and Nano-Liquid Chromatography Electrospray Ionization Mass Spectrometry for the Characterization of Post-translationally Modified Histones*, *Mol. Cell. Proteomics*, **2013**, 12, 2640-2656.
- (200) Wang, Y., et al. *Improving the comprehensiveness and sensitivity of sheathless capillary electrophoresis-tandem mass spectrometry for proteomic analysis*, *Anal. Chem.*, **2012**, 84, 8505-8513.
- (201) Huffman, J.E., et al. *Comparative performance of four methods for high-throughput glycosylation analysis of immunoglobulin G in genetic and epidemiological research*, *Mol. Cell. Proteomics*, **2014**, 13, 1598-1610.
- (202) Jansen, B.C., et al. *MassyTools: A High-Throughput Targeted Data Processing Tool for Relative Quantitation and Quality Control Developed for Glycomic and Glycoproteomic MALDI-MS*, *J. Proteome Res.*, **2015**, 14, 5088-5098.
- (203) Reusch, D., et al. *Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 2: Mass spectrometric methods*, *MABs*, **2015**, 7, 732-742.
- (204) Breadmore, M.C., et al. *Recent advances in enhancing the sensitivity of electrophoresis and electrochromatography in capillaries and microchips (2010-2012)*, *Electrophoresis*, **2013**, 34, 29-54.
- (205) Timerbaev, A.R.; Hirokawa, T. *Recent advances of transient isotachopheresis-capillary electrophoresis in the analysis of small ions from high-conductivity matrices*, *Electrophoresis*, **2006**, 27, 323-340.
- (206) Sanz-Nebot, V., et al. *Comparison of sheathless and sheath-flow electrospray interfaces for the capillary electrophoresis-electrospray ionization-mass spectrometry analysis of peptides*, *Electrophoresis*, **2005**, 26, 1457-1465.
- (207) Selman, M.H., et al. *Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface*, *J. Proteomics*, **2012**, 75, 1318-1329.
- (208) Bladergroen, M.R., et al. *Automation of High-Throughput Mass Spectrometry-Based Plasma N-Glycome Analysis with Linkage-Specific Sialic Acid Esterification*, *J. Proteome Res.*, **2015**, 14, 4080-4086.
- (209) Jefferis, R. *Glycosylation as a strategy to improve antibody-based therapeutics*, *Nat. Rev. Drug Discov.*, **2009**, 8, 226-234.
- (210) Varki, A. *Biological roles of oligosaccharides: all of the theories are correct*, *Glycobiology*, **1993**, 3, 97-130.
- (211) Ehrmann, B.M., et al. *Relative importance of basicity in the gas phase and in solution for determining selectivity in electrospray ionization mass spectrometry*, *J. Am. Soc. Mass. Spectrom.*, **2008**, 19, 719-728.

- (212) Kim, K., et al. *Evaluation of glycomic profiling as a diagnostic biomarker for epithelial ovarian cancer*, *Cancer Epidemiol., Biomarkers Prev.*, **2014**, 23, 611-621.
- (213) Rombouts, Y., et al. *Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis*, *Ann. Rheum. Dis.*, **2015**, 74, 234-241.
- (214) Vermassen, T., et al. *Glycosylation of prostate specific antigen and its potential diagnostic applications*, *Clin. Chim. Acta*, **2012**, 413, 1500-1505.
- (215) Anderson, N.L., et al. *A Human Proteome Detection and Quantitation Project*, *Mol. Cell. Proteomics*, **2009**, 8, 883-886.
- (216) Snyder, C.M., et al. *Capillary electrophoresis-mass spectrometry for direct structural identification of serum N-glycans*, *J. Chromatogr. A*, **2017**, 1523, 127-139.
- (217) Mitra, I., et al. *Structural Characterization of Serum N-Glycans by Methylamidation, Fluorescent Labeling, and Analysis by Microchip Electrophoresis*, *Anal. Chem.*, **2016**, 88, 8965-8971.
- (218) Maxwell, E.J., et al. *A promising capillary electrophoresis-electrospray ionization-mass spectrometry method for carbohydrate analysis*, *Electrophoresis*, **2011**, 32, 2161-2166.
- (219) Gennaro, L.A., et al. *Capillary electrophoresis/electrospray ion trap mass spectrometry for the analysis of negatively charged derivatized and underivatized glycans*, *Rapid Commun. Mass Spectrom.*, **2002**, 16, 192-200.
- (220) Zhong, X., et al. *Capillary Electrophoresis-Electrospray Ionization-Mass Spectrometry for Quantitative Analysis of Glycans Labeled with Multiplex Carbonyl-Reactive Tandem Mass Tags*, *Anal. Chem.*, **2015**, 87, 6527-6534.
- (221) Khatri, K., et al. *Microfluidic Capillary Electrophoresis-Mass Spectrometry for Analysis of Monosaccharides, Oligosaccharides, and Glycopeptides*, *Anal. Chem.*, **2017**, 89, 6645-6655.
- (222) Holst, S., et al. *Linkage-Specific in Situ Sialic Acid Derivatization for N-Glycan Mass Spectrometry Imaging of Formalin-Fixed Paraffin-Embedded Tissues*, *Anal. Chem.*, **2016**, 88, 5904-5913.
- (223) Nishikaze, T., et al. *Differentiation of Sialyl Linkage Isomers by One-Pot Sialic Acid Derivatization for Mass Spectrometry-Based Glycan Profiling*, *Anal. Chem.*, **2017**, 89, 2353-2360.
- (224) Wheeler, S.F., et al. *Derivatization of sialic acids for stabilization in matrix-assisted laser desorption/ionization mass spectrometry and concomitant differentiation of alpha(2 -> 3)- and alpha(2 -> 6)-isomers*, *Rapid Commun. Mass Spectrom.*, **2009**, 23, 303-312.
- (225) Lattova, E.; Perreault, H. *The usefulness of hydrazine derivatives for mass spectrometric analysis of carbohydrates*, *Mass. Spectrom. Rev.*, **2013**, 32, 366-385.
- (226) Kammeijer, G.S.M., et al. *Dopant Enriched Nitrogen Gas Combined with Sheathless Capillary Electrophoresis-Electrospray Ionization-Mass Spectrometry for Improved Sensitivity and Repeatability in Glycopeptide Analysis*, *Anal. Chem.*, **2016**, 88, 5849-5856.
- (227) Li, H.H., et al. *MALDI-MS analysis of sialylated N-glycan linkage isomers using solid-phase two step derivatization method*, *Anal. Chim. Acta*, **2016**, 924, 77-85.
- (228) Yamada, K.; Kakehi, K. *Recent advances in the analysis of carbohydrates for biomedical use*, *J. Pharmaceut. Biomed.*, **2011**, 55, 702-727.
- (229) Ruhaak, L.R., et al. *Glycan labeling strategies and their use in identification and quantification*, *Anal. Bioanal. Chem.*, **2010**, 397, 3457-3481.
- (230) Kalia, J.; Raines, R.T. *Hydrolytic stability of hydrazones and oximes*, *Angew. Chem. Int. Edit*, **2008**, 47, 7523-7526.
- (231) Naven, T.J.P.; Harvey, D.J. *Cationic Derivatization of Oligosaccharides with Girard's T Reagent for Improved Performance in Matrix-assisted Laser*



- Desorption/Ionization and Electrospray Mass Spectrometry, Rapid Commun. Mass Spectrom.*, **1996**, 10, 829-834.
- (232) Walker, S.H., et al. *Hydrophobic derivatization of N-linked glycans for increased ion abundance in electrospray ionization mass spectrometry*, *J. Am. Soc. Mass Spectrom.*, **2011**, 22, 1309-1317.
- (233) Wang, C., et al. *Simplified quantitative glycomics using the stable isotope label Girard's reagent p by electrospray ionization mass spectrometry*, *J. Proteome Res.*, **2014**, 13, 372-384.
- (234) Walker, S.H., et al. *Interplay of permanent charge and hydrophobicity in the electrospray ionization of glycans*, *Anal. Chem.*, **2010**, 82, 6636-6642.
- (235) Johnson, P.H., et al. *Purification, properties and possible gene assignment of an alpha 1,3-fucosyltransferase expressed in human liver*, *Glycoconj. J.*, **1995**, 12, 879-893.
- (236) Johnson, P.H., et al. *Reassessment of the acceptor specificity and general properties of the Lewis blood-group gene associated alpha-3/4-fucosyltransferase purified from human milk*, *Glycoconj. J.*, **1992**, 9, 251-264.
- (237) Sarmini, K.; Kenndler, E. *Influence of organic solvents on the separation selectivity in capillary electrophoresis*, *J. Chromatogr. A*, **1997**, 792, 3-11.
- (238) Tran, A.D., et al. *Separation of Carbohydrate-Mediated Microheterogeneity of Recombinant-Human-Erythropoietin by Free Solution Capillary Electrophoresis - Effects of Ph, Buffer Type and Organic Additives*, *J. Chromatogr.*, **1991**, 542, 459-471.
- (239) Pabst, M., et al. *Comparison of fluorescent labels for oligosaccharides and introduction of a new postlabeling purification method*, *Anal. Biochem.*, **2009**, 384, 263-273.
- (240) Mottet, N., et al. *EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent*, *Eur. Urol.*, **2017**, 71, 618-629.
- (241) Barrabés, S., et al. *Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer*, *Clin. Chim. Acta*, **2017**, 470, 97-102.
- (242) Saerens, D., et al. *Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen*, *J. Biol. Chem.*, **2004**, 279, 51965-51972.
- (243) Gornik, O., et al. *Stability of N-glycan profiles in human plasma*, *Glycobiology*, **2009**, 19, 1547-1553.
- (244) Isono, T., et al. *Structural diversity of cancer-related and non-cancer-related prostate-specific antigen*, *Clin. Chem.*, **2002**, 48, 2187-2194.
- (245) Stura, E.A., et al. *Crystal structure of human prostate-specific antigen in a sandwich antibody complex*, *J. Mol. Biol.*, **2011**, 414, 530-544.
- (246) Hessels, D., et al. *Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer*, *Clin. Cancer Res.*, **2007**, 13, 5103-5108.
- (247) Iribarne, J.V.; Thomson, B.A. *On the evaporation of small ions from charged droplets*, *J. Chem. Phys.*, **1976**, 64, 2287-2294.
- (248) Konermann, L., et al. *Unraveling the mechanism of electrospray ionization*, *Anal. Chem.*, **2013**, 85, 2-9.
- (249) Iavarone, A.T.; Williams, E.R. *Mechanism of charging and supercharging molecules in electrospray ionization*, *J. Am. Soc. Mass. Spectrom.*, **2003**, 125, 2319-2327.
- (250) Hunter, E.P.L.; Lias, S.G. *Evaluated gas phase basicities and proton affinities of molecules: An update*, *J. Phys. Chem. Ref. Data*, **1998**, 27, 413-656.
- (251) Zhou, S.Y., et al. *Isomeric Separation of Permethylated Glycans by Porous Graphitic Carbon (PGC)-LC-MS/MS at High Temperatures*, *Anal. Chem.*, **2017**, 89, 6590-6597.
- (252) Heemskerk, A.A.M. *Exploring the proteome by CE-ESI-MS - Chapter 3 - Optimization of capillary electrophoresis-mass*

- spectrometry loadability and separation power. Leiden University Medical Center, Leiden, The Netherlands, **2016**.
- (253) Nature: Retrieved from <https://www.nature.com/subjects/personalized-medicine>, Description of Personalized Medicine.
- (254) VVD, et al.: Regeerakkoord 'Vertrouwen in de toekomst' - 2017-2021, **2017**.
- (255) Hsu, K.L.; Mahal, L.K. Sweet tasting chips: microarray-based analysis of glycans, *Curr. Opin. Chem. Biol.*, **2009**, 13, 427-432.
- (256) Svarovsky, S.A.; Joshi, L. Cancer glycan biomarkers and their detection - past, present and future, *Anal. Methods*, **2014**, 6, 3918-3936.
- (257) National Cancer Institute, Dictionary of Cancer Terms - Biomarker - Retrieved from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker>.
- (258) Henry, N.L.; Hayes, D.F. Cancer biomarkers, *Mol. Oncol.*, **2012**, 6, 140-146.
- (259) Ransohoff, D.F. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design, *J. Clin. Epidemiol.*, **2007**, 60, 1205-1219.
- (260) Horvath, A.R., et al. From biomarkers to medical tests: the changing landscape of test evaluation, *Clin. Chim. Acta*, **2014**, 427, 49-57.
- (261) Monaghan, P.J., et al. Biomarker development targeting unmet clinical needs, *Clin. Chim. Acta*, **2016**, 460, 211-219.
- (262) Eggener, S.E., et al. Prostate Cancer Screening, *JAMA*, **2015**, 314, 825-826.
- (263) Santos, M.R., et al. Separation and Analysis of Intact Prostate Specific Antigen (PSA) and its Proteoforms by CESI-MS Under Native and Denaturing Conditions. SCIEX, **2015**; https://scix.jp/Documents/tech%20notes/CESI-MS_Intact_Native_Protein_Proteoforms_PSA.pdf
- (264) Mattsson, J.M., et al. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid, *Prostate*, **2008**, 68, 945-954.
- (265) Stamey, T.A., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate, *N. Engl. J. Med.*, **1987**, 317, 909-916.
- (266) Gutman, A.B.; Gutman, E.B. An "Acid" Phosphatase Occurring in the Serum of Patients with Metastasizing Carcinoma of the Prostate Gland, *J. Clin. Invest.*, **1938**, 17, 473-478.
- (267) Tabares, G., et al. Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples, *Clin. Biochem.*, **2007**, 40, 343-350.
- (268) Clark, D.; Mao, L. Cancer biomarker discovery: lectin-based strategies targeting glycoproteins, *Dis. Markers*, **2012**, 33, 1-10.
- (269) Heemskerk, A.A.M., et al. CE-ESI-MS for bottom-up proteomics: Advances in separation, interfacing and applications, *Mass. Spectrom. Rev.*, **2016**, 35, 259-271.
- (270) Breadmore, M.C., et al. Recent advances in enhancing the sensitivity of electrophoresis and electrochromatography in capillaries and microchips (2008-2010), *Electrophoresis*, **2011**, 32, 127-148.
- (271) Medina-Casanellas, S., et al. Low-picomolar analysis of peptides by on-line coupling of fritless solid-phase extraction to sheathless capillary electrophoresis-mass spectrometry, *J. Chromatogr. A*, **2014**, 1328, 1-6.
- (272) Zhang, Z., et al. Integrated strong cation-exchange hybrid monolith coupled with capillary zone electrophoresis and simultaneous dynamic pH junction for large-volume proteomic analysis by mass spectrometry, *Talanta*, **2015**, 138, 117-122.
- (273) Guo, X., et al. Capillary Electrophoresis-Nanoelectrospray Ionization-Selected Reaction Monitoring Mass Spectrometry via a True Sheathless Metal-Coated Emitter Interface for Robust and High-Sensitivity Sample Quantification, *Anal. Chem.*, **2016**, 88, 4418-4425.
- (274) Konášová, R., et al. Comparison of two low flow interfaces for measurement



of mobilities and stability constants by affinity capillary electrophoresis-mass spectrometry, *J. Chromatogr. A*, **2018**, DOI: 10.1016/j.chroma.2018.07.014.

- (275) Sun, L., et al. *Third-generation electrokinetically pumped sheath-flow nanospray interface with improved stability and sensitivity for automated capillary zone electrophoresis-mass spectrometry analysis of complex proteome digests*, *J. Proteome Res.*, **2015**, 14, 2312-2321.
- (276) Guzman, N.A., et al. *Immunoaffinity capillary electrophoresis as a powerful strategy for the quantification of low-abundance biomarkers, drugs, and metabolites in biological matrices*, *Electrophoresis*, **2008**, 29, 3259-3278.
- (277) DiBattista, A., et al. *High Throughput Screening Method for Systematic Surveillance of Drugs of Abuse by Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry*, *Anal. Chem.*, **2017**, 89, 11853-11861.
- (278) Zhang, S., et al. *Profiling B-Type Natriuretic Peptide Cleavage Peptidoforms in Human Plasma by Capillary Electrophoresis with Electrospray Ionization Mass Spectrometry*, *J. Proteome Res.*, **2017**, 16, 4515-4522.
- (279) Clerc, F., et al. *Plasma N-Glycan Signatures Associate With Features of Inflammatory Bowel Diseases*, *Gastroenterology*, **2018**, DOI: 10.1053/j.gastro.2018.05.030.